ATE314076T1 - Fosinopril-formulierung - Google Patents
Fosinopril-formulierungInfo
- Publication number
- ATE314076T1 ATE314076T1 AT03706893T AT03706893T ATE314076T1 AT E314076 T1 ATE314076 T1 AT E314076T1 AT 03706893 T AT03706893 T AT 03706893T AT 03706893 T AT03706893 T AT 03706893T AT E314076 T1 ATE314076 T1 AT E314076T1
- Authority
- AT
- Austria
- Prior art keywords
- fosinopril
- formulation
- fosinoprilat
- ace
- prodrug
- Prior art date
Links
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 3
- 229960002490 fosinopril Drugs 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 abstract 1
- BYNVYIUJKRRNNC-UHFFFAOYSA-N docosanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCCCCCC(O)=O BYNVYIUJKRRNNC-UHFFFAOYSA-N 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- WOIWWYDXDVSWAZ-RTWAWAEBSA-N fosinoprilat Chemical compound C([C@@H](C[C@H]1C(=O)O)C2CCCCC2)N1C(=O)CP(O)(=O)CCCCC1=CC=CC=C1 WOIWWYDXDVSWAZ-RTWAWAEBSA-N 0.000 abstract 1
- 229960003018 fosinoprilat Drugs 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IS6315A IS1935B (is) | 2002-03-19 | 2002-03-19 | Fósínópríl lyfjasamsetning |
| PCT/IS2003/000013 WO2003077929A1 (en) | 2002-03-19 | 2003-03-19 | Fosinopril formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE314076T1 true ATE314076T1 (de) | 2006-01-15 |
Family
ID=36715398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03706893T ATE314076T1 (de) | 2002-03-19 | 2003-03-19 | Fosinopril-formulierung |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7045511B2 (de) |
| EP (1) | EP1531831B1 (de) |
| AT (1) | ATE314076T1 (de) |
| AU (1) | AU2003208599A1 (de) |
| DE (1) | DE60303041T2 (de) |
| DK (1) | DK1531831T3 (de) |
| EA (1) | EA008171B1 (de) |
| ES (1) | ES2256721T3 (de) |
| IS (1) | IS1935B (de) |
| NO (1) | NO20044390L (de) |
| PT (1) | PT1531831E (de) |
| UA (1) | UA78988C2 (de) |
| WO (1) | WO2003077929A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2322854T3 (es) * | 2003-06-26 | 2009-06-30 | Teva Pharmaceutical Industries Limited | Composiciones farmaceuticas estables de derivados del acido 2-aza-biciclo(3.3.0)-octano-3-carboxilico. |
| US20050095287A1 (en) * | 2003-10-29 | 2005-05-05 | Matharu Amol S. | Fosinopril composition |
| GB2411355B (en) * | 2004-02-27 | 2006-02-22 | Niche Generics Ltd | Pharmaceutical composition |
| MX2007008392A (es) * | 2005-02-11 | 2007-09-06 | Aventis Pharma Inc | Esteres de acido propano-fosfinico sustituido. |
| WO2006100602A2 (en) * | 2005-03-22 | 2006-09-28 | Aurobindo Pharma Ltd | Immediate release stable solid oral dosage forms op fosinopril |
| KR20080112387A (ko) * | 2006-04-19 | 2008-12-24 | 테바 파마슈티컬 인더스트리즈 리미티드 | 2-아자-비사이클로[3.3.0]-옥탄-3-카르복실산 유도체의 안정한 약학 조성물 |
| GB0612540D0 (en) * | 2006-06-23 | 2006-08-02 | Novartis Ag | Galenical formulations of organic compounds |
| ATE406173T1 (de) * | 2006-07-10 | 2008-09-15 | Teva Pharma | Stabile zubereitung enthaltend eine kombination aus einer feuchtigkeitsempfindlichen aktiven substanz und einer zweiten aktiven substanz und verfahren zur herstellung der zubereitung. |
| US20140179712A1 (en) | 2012-12-21 | 2014-06-26 | Astrazeneca Ab | Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4337201A (en) * | 1980-12-04 | 1982-06-29 | E. R. Squibb & Sons, Inc. | Phosphinylalkanoyl substituted prolines |
| US5006344A (en) | 1989-07-10 | 1991-04-09 | E. R. Squibb & Sons, Inc. | Fosinopril tablet formulations |
| US6521647B2 (en) * | 2000-04-04 | 2003-02-18 | Pfizer Inc. | Treatment of renal disorders |
| CA2330904C (en) * | 2001-01-11 | 2006-10-24 | Bernard Charles Sherman | Fosinopril sodium tablet formulation |
| JP2005508978A (ja) * | 2001-11-02 | 2005-04-07 | ファイザー・プロダクツ・インク | Pde9阻害薬によるインスリン抵抗性症候群及び2型糖尿病の治療 |
| ITMI20012366A1 (it) * | 2001-11-09 | 2003-05-09 | Farmatron Ltd | Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali |
-
2002
- 2002-03-19 IS IS6315A patent/IS1935B/is unknown
-
2003
- 2003-03-19 DE DE60303041T patent/DE60303041T2/de not_active Expired - Lifetime
- 2003-03-19 AT AT03706893T patent/ATE314076T1/de active
- 2003-03-19 EA EA200401218A patent/EA008171B1/ru not_active IP Right Cessation
- 2003-03-19 WO PCT/IS2003/000013 patent/WO2003077929A1/en not_active Ceased
- 2003-03-19 ES ES03706893T patent/ES2256721T3/es not_active Expired - Lifetime
- 2003-03-19 AU AU2003208599A patent/AU2003208599A1/en not_active Abandoned
- 2003-03-19 DK DK03706893T patent/DK1531831T3/da active
- 2003-03-19 US US10/507,918 patent/US7045511B2/en not_active Expired - Fee Related
- 2003-03-19 PT PT03706893T patent/PT1531831E/pt unknown
- 2003-03-19 UA UA20041008392A patent/UA78988C2/uk unknown
- 2003-03-19 EP EP03706893A patent/EP1531831B1/de not_active Expired - Lifetime
-
2004
- 2004-10-18 NO NO20044390A patent/NO20044390L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2256721T3 (es) | 2006-07-16 |
| US7045511B2 (en) | 2006-05-16 |
| EP1531831A1 (de) | 2005-05-25 |
| DK1531831T3 (da) | 2006-05-15 |
| US20050256086A1 (en) | 2005-11-17 |
| IS6315A (is) | 2003-09-20 |
| UA78988C2 (en) | 2007-05-10 |
| WO2003077929A1 (en) | 2003-09-25 |
| NO20044390L (no) | 2004-12-15 |
| PT1531831E (pt) | 2006-05-31 |
| EA200401218A1 (ru) | 2005-12-29 |
| DE60303041T2 (de) | 2006-08-24 |
| DE60303041D1 (de) | 2006-02-02 |
| IS1935B (is) | 2004-06-16 |
| AU2003208599A1 (en) | 2003-09-29 |
| EA008171B1 (ru) | 2007-04-27 |
| EP1531831B1 (de) | 2005-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5590918A2 (es) | Formulaciones | |
| CY1109457T1 (el) | Παραγωγο aminoαλκοολης ή παραγωγο φωσφονικου οξεος και φαρμακευτικη συνθεση που τα περιεχει | |
| MA29854B1 (fr) | Nouvelle formulation | |
| MXPA04004464A (es) | Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades. | |
| MA29857B1 (fr) | Derives de triazolopyridine en tant qu'inhibiteurs de lipases et phospholipases | |
| MY138252A (en) | Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease | |
| NO20081050L (no) | Kaspaseinhibitor-prodroger | |
| SG10201809390QA (en) | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | |
| NO20060847L (no) | Substituert 2-aminotetralin til behandling av depresjon | |
| ATE554084T1 (de) | N-hydroxyacrylamidverbindungen | |
| MX2009003926A (es) | Composiciones de fenilalquilamino-carbamato. | |
| NO20074544L (no) | Inhibering av HER2-losriving med matriksmetalloproteaseantagonister | |
| MX2009003929A (es) | Composiciones de fenilalquil carbamato. | |
| MA29278B1 (fr) | Composition pharmaceutique comprenant un derive de l'indolylmaleimide | |
| MXPA04006266A (es) | Pirimidotriazinas como inhibidores de fosfatasa. | |
| ATE314076T1 (de) | Fosinopril-formulierung | |
| BR0112245B1 (pt) | Éster de ácido 4-alcóxi-ciclohexano-1-amino-carboxílico | |
| EA200601608A1 (ru) | Способ производства твёрдой фармацевтической композиции | |
| WO2008036316A3 (en) | Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | |
| ATE464043T1 (de) | Pharmazeutische zusammensetzung enthaltend l- arginin | |
| BRPI0411218A (pt) | formulações alvejantes fluorescentes estáveis em estocagem | |
| TNSN06012A1 (en) | Emulsifying systems containing azetidine derivatives | |
| WO2006031929A3 (en) | Thiazolopyridine kinase inhibitors | |
| EA200801634A1 (ru) | Твердая фармацевтическая композиция, содержащая ирбесартан | |
| TW200640860A (en) | Lercanidipine free base |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1531831 Country of ref document: EP |